Related Experiment Video
Updated: Mar 6, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
Manish K Thakur1, Antoinette J Wozniak1
1Department of Oncology, Karmanos Cancer Center, Detroit, MI, USA.
Abstract:
The treatment options for metastatic non-small-cell lung cancer (NSCLC) have expanded dramatically in the last 10 years with the discovery of newer drugs and targeted therapy. Epidermal growth factor receptor (EGFR), when aberrantly activated, promotes cell growth and contributes in various ways to the malignant process. EGFR has become an important therapeutic target in a variety of malignancies. Small-molecule tyrosine kinase inhibitors (TKIs) of EGFR are being used to treat advanced NSCLC and are particularly effective in the presence of EGFR mutations. Monoclonal antibodies have also been developed that block the EGFR at the cell surface and work in conjunction with chemotherapy. Necitumumab is a second-generation fully human IgG1 monoclonal antibody that has shown promise in metastatic NSCLC. The benefit has mostly been restricted to squamous cell lung cancer in the frontline setting. Considering that the survival advantage for these patients was modest, there is a need to discover biomarkers that will predict which patients will likely have the best outcomes. This review focuses on the development and clinical trial experience with necitumumab in NSCLC.
Insights
Necitumumab, an EGFR-targeting antibody, shows promise for metastatic non-small-cell lung cancer (NSCLC), particularly squamous cell type. Further research is needed to identify biomarkers for optimal patient selection and improved outcomes.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Metastatic non-small-cell lung cancer (NSCLC) treatment has advanced with targeted therapies.
- Epidermal growth factor receptor (EGFR) is a key target in various cancers, including NSCLC.
- EGFR inhibitors, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, are crucial in NSCLC treatment.
Purpose of the Study:
- To review the development and clinical trial experience of necitumumab in metastatic NSCLC.
- To highlight necitumumab's efficacy, particularly in squamous cell lung cancer.
- To emphasize the need for biomarkers to predict patient response to necitumumab.
Main Methods:
- Review of clinical trial data for necitumumab in metastatic NSCLC.
- Analysis of necitumumab's mechanism of action as an EGFR-blocking monoclonal antibody.
- Evaluation of necitumumab's efficacy and safety in different NSCLC subtypes and treatment settings.
Main Results:
- Necitumumab, a fully human IgG1 monoclonal antibody, demonstrated potential in metastatic NSCLC.
- The primary benefit of necitumumab was observed in the frontline treatment of squamous cell lung cancer.
- The survival advantage associated with necitumumab was modest, indicating a need for predictive biomarkers.
Conclusions:
- Necitumumab represents a therapeutic option for specific NSCLC patient populations.
- Identifying predictive biomarkers is essential for optimizing necitumumab use and improving patient outcomes.
- Further research into necitumumab and biomarker discovery is warranted for advanced NSCLC.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...